Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Assets (2020 - 2026)

Barinthus Biotherapeutics (BRNS) has disclosed Assets for 7 consecutive years, with $92.1 million as the latest value for Q1 2026.

  • For Q1 2026, Assets fell 35.11% year-over-year to $92.1 million; the TTM value through Mar 2026 reached $92.1 million, down 35.11%, while the annual FY2025 figure was $98.2 million, 38.77% down from the prior year.
  • Assets hit $92.1 million in Q1 2026 for Barinthus Biotherapeutics, down from $98.2 million in the prior quarter.
  • Across five years, Assets topped out at $286.1 million in Q1 2022 and bottomed at $92.1 million in Q1 2026.
  • Average Assets over 5 years is $198.6 million, with a median of $199.5 million recorded in 2024.
  • Year-over-year, Assets soared 71.85% in 2022 and then tumbled 42.13% in 2025.
  • Barinthus Biotherapeutics' Assets stood at $270.2 million in 2022, then fell by 20.61% to $214.5 million in 2023, then fell by 25.26% to $160.3 million in 2024, then plummeted by 38.77% to $98.2 million in 2025, then dropped by 6.14% to $92.1 million in 2026.
  • According to Business Quant data, Assets over the past three periods came in at $92.1 million, $98.2 million, and $109.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.